• Publications
  • Influence
Multicenter phase II study of Apatinib in non-triple-negative metastatic breast cancer
BackgroundApatinib is a tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor 2(VEGFR-2). This study was conducted to assess the efficacy and safety of apatinib in patientsExpand
  • 120
  • 6
Effect of Fruquintinib vs Placebo on Overall Survival in Patients With Previously Treated Metastatic Colorectal Cancer: The FRESCO Randomized Clinical Trial
Importance Patients with metastatic colorectal cancer (CRC) have limited effective and tolerable treatment options. Objective To evaluate the efficacy and safety of oral fruquintinib, a vascularExpand
  • 57
  • 5
ATF4 Regulates CD4+ T Cell Immune Responses through Metabolic Reprogramming
SUMMARY T cells are strongly regulated by oxidizing environments and amino acid restriction. How T cells reprogram metabolism to adapt to these extracellular stress situations is not well understood.Expand
  • 29
  • 5
Prospective study of chemotherapy in combination with cytokine-induced killer cells in patients suffering from advanced non-small cell lung cancer.
The present study evaluated the clinical efficacy of chemotherapy in combination with cytokine-induced killer (CIK) biotherapy compared to the chemotherapy alone. Fifty-nine advanced non-small cellExpand
  • 121
  • 4
PD-1 Blockade Boosts Radiofrequency Ablation–Elicited Adaptive Immune Responses against Tumor
Purpose: Radiofrequency ablation (RFA) has been shown to elicit tumor-specific T-cell immune responses, but is not sufficient to prevent cancer progression. Here, we investigated immune-suppressiveExpand
  • 81
  • 4
  • PDF
B7-H6 expression correlates with cancer progression and patient's survival in human ovarian cancer.
B7-H6, a newly identified B7 family member molecule, binds to its receptor on NK cells, NKp30, and then triggers the anti-tumor NK cell cytotoxicity and leads to the cytokine secretion. As of now,Expand
  • 47
  • 4
A Randomized Multicenter Phase III Study of Single Administration of Mecapegfilgrastim (HHPG-19K), a Pegfilgrastim Biosimilar, for Prophylaxis of Chemotherapy-Induced Neutropenia in Patients With
BACKGROUND Mecapegfilgrastim (code name HHPG-19K) is a biosimilar to pegylated recombinant human granulocyte-colony stimulating factor (PEG-rhG-CSF). The efficacy and safety of mecapegfilgrastim,Expand
  • 12
  • 4
Brivanib as adjuvant therapy to transarterial chemoembolization in patients with hepatocellular carcinoma: A randomized phase III trial
Transarterial chemoembolization (TACE) is the current standard of treatment for unresectable intermediate‐stage hepatocellular carcinoma (HCC). Brivanib, a selective dual inhibitor of vascularExpand
  • 169
  • 3
  • PDF
Cytokine-induced killer cells promote antitumor immunity
The number of immune cells, especially dendritic cells and cytotoxic tumor infiltrating lymphocytes (TIL), particularly Th1 cells, CD8 T cells, and NK cells is associated with increased survival ofExpand
  • 114
  • 3
PD-1/PD-L1 expression in non-small-cell lung cancer and its correlation with EGFR/KRAS mutations
ABSTRACT This study was aimed to detect the correlation among EGFR/KRAS status and PD-1/PD-L1 expression in non-small-cell lung cancer (NSCLC) patients. PD-1 and PD-L1 expressions were detected byExpand
  • 75
  • 3